KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences Javascript is ...
Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today ...
Stay confident in today’s economy with useful tips and enter our $26K Sweepstakes! Help Register Login Login Hi, %{firstName} ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results